Comparative effectiveness of exercise and drug interventions on mortality outcomes: Metaepidemiological study

British Journal of Sports Medicine

Volumn 49, Issue 21, 2015, Pages 1414-1422

  Naci, Huseyin ^a,b   Ioannidis, John P A ^c  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CORONARY DISEASE; HEART FAILURE; HUMAN; KINESIOTHERAPY; META ANALYSIS; MORTALITY; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE REHABILITATION; TREATMENT OUTCOME;

ANTICOAGULANTS; CORONARY DISEASE; DIURETICS; DRUG THERAPY; EXERCISE THERAPY; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; PLATELET AGGREGATION INHIBITORS; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; STROKE REHABILITATION; TREATMENT OUTCOME;

EID: 84945207711     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsports-2015-f5577rep     Document Type: Article

References (68)

1. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports 2006;16:3-63.
2. Roddy E, Zhang W, Doherty M. Aerobic walking orstrengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis 2005;64: 544-8.
3. Knols R, Aaronson NK, Uebelhart D, et al. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol 2005;23:3830-42.
4. Fong DYT, Ho JWC, Hui BPH, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ 2012;344:e70.
5. Sigal RJ, Kenny GP, Wasserman DH, et al. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006;29:1433-8.
6. Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits and recommendations for physical activity programs for all americans: a statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996;94:857-62.
7. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006;61:772-8.
8. Kujala UM. Evidence for exercise therapy in the treatment of chronic disease based on at least three randomized controlled trials-summary of published systematic reviews. Scand J Med Sci Sports 2004;14:339-45.
9. Kujala UM. Evidence on the effects of exercise therapy in the treatment of chronic disease. Br J Sports Med 2009;43:550-5.
10. Byberg L, Melhus H, Gedeborg R, et al. Total mortality after changes in leisure time physical activity in 50 year old men: 35 year follow-up of population based cohort. BMJ 2009;338:b688.
11. Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. Int J Epidemiol 2011;40:1382-400.
12. Wen CP, Wai JPM, Tsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2011;378:1244-53.
13. Blair SN. Physical inactivity: the biggest public health problem ofthe 21st century. Br J Sports Med 2009;43:1-2.
14. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990?2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-60.
15. Department of Health. UK physical activity guidelines. DoH, 2011.
16. Townsend N, Bhatnagar P, Wickramasinghe K, et al. Physical activity statistics 2012. British Heart Foundation, 2012.
17. NHS Information System. Prescriptions dispensed in the community: England, Statistics for 2001-2011. NHS Information System, 2012.
18. Naci H, Brugts JJ, Fleurence R, et al. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol 2013;20:641-57.
19. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med2004;116:682-92.
20. Higgins JP, Green S, Collaboration C. Cochrane handbook for systematic reviews of interventions: Wiley Online Library, 2008.
21. Salanti G, Higgins JP, Ades A, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
22. Salanti G, Kavvoura FK, Ioannidis JP. Exploring the geometry of treatment networks. Ann Intern Med 2008;148:544-53.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
24. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
25. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013;346:f2914.
26. Dias S, Sutton AJ, Ades AE, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. www.nicedsu.org.uk.
27. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17.
28. Cooper NJ, Sutton AJ, Morris D, et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009;28:1861-81.
29. Borenstein M, Hedges LV, Higgins JPT, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Method 2010;1:97-111.
30. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
31. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
32. Song F, Xiong T, Parekh-Bhurke S, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 2011;343:d4909.
33. Heran BS, Chen JM, Ebrahim S, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2011:CD001800.
34. Brazzelli M, Saunders DH, Greig CA, et al. Physical fitness training for stroke patients. Cochrane Database Syst Rev 2011:CD003316.
35. Davies EJ, Moxham T, Rees K, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2010:CD003331.
36. Hopper I, Billah B, Skiba M, et al. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil 2011;18: 813-23.
37. Freemantle N, Cleland J, Young P, et al. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
38. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. JAm Coll Cardiol 1999;33: 598-604.
39. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
40. Sandercock PA, Counsell C, Kamal AK. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2008:CD000024.
41. Sandercock PA, Counsell C, Gubitz GJ, et al. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008:CD000029.
42. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009:CD000213.
43. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
44. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012:CD003838.
45. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013;346:f55.
46. Heran BS, Musini VM, Bassett K, et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 2012:CD003040.
47. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev 2002:CD003242.
48. Moynihan R, Smith R. Too much medicine? BMJ 2002;324:859-60.
49. Getz L, Luise Kirkengen A, Hetlevik I, et al. Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study. Scand J Prim Health Care 2004;22:202-8.
50. Westin S, Heath I. Thresholds for normal blood pressure and serum cholesterol. BMJ 2005;330:1461-2.
51. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
52. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
53. Khan KM, Weiler R, Blair SN. Prescribing exercise in primary care. BMJ 2011;343: d4141.
54. Warburton DER, Nicol CW, Bredin SSD. Prescribing exercise as preventive therapy. CMAJ 2006;174:961-74.
55. Barnes P, Schoenborn C. Trends in adults receiving a recommendation for exercise or other physical activity from a physician or other health professional. In: US Centers for Disease Control and Prevention, ed. 2012.
56. Pavey TG, Taylor AH, Fox KR, et al. Effect of exercise referral schemes in primary care on physical activity and improving health outcomes: systematic review and meta-analysis. BMJ 2011;343:d6462.
57. Orrow G, Kinmonth A-L, Sanderson S, et al. Effectiveness of physical activity promotion based in primary care: systematic review and meta-analysis of randomised controlled trials. BMJ 2012;344:e1389.
58. Williams NH. Promoting physical activity in primary care. BMJ 2011;343:d6615.
59. Belardinelli R, Georgiou D, Cianci G, et al. 10-yearexercise training in chronicheart failure: a randomized controlled trial. J Am Coll Cardiol 2012;60: 1521-8.
60. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001;345:892-902.
61. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med2013;11:159.
62. Davidson PM, Cockburn J, Newton PJ, et al. Can a heartfailure-specific cardiac rehabilitation program decrease hospitalizations and improve outcomes in high-risk patients? Eur J Cardiovasc Prev Rehabil2010;17:393-402.
63. West RR, Jones DA, Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlledtrial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. Heart 2012;98:637-44.
64. Pereira TV, Ioannidis J. Statisticallysignificant meta-analyses of clinical trials have modest credibility and inflated effects. J Clin Epidemiol 2011;64:1060-9.
65. Thompson PD, Parker B. Statins, exercise, exercise training. JAm Coll Cardiol 2013;62:715-6.
66. Cartwright N, Hardie J. Evidence-based policy: a practical guide to doing it better. Oxford University Press, 2012.
67. Sorenson C, Naci H, Cylus J, et al. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ 2011;343:d4849.
68. Naci H, Cylus J, Vandoros S, et al. Raising the bar for market authorisation of new drugs. BMJ 2012;345:e4261.